Angiogenesis-targeted therapies in prostate cancer

Clinical Prostate Cancer

Volumn 3, Issue 3, 2004, Pages 165-173

  Lara Jr , Primo N ^a,b   Twardowski, Przemyslaw ^b,c   Quinn, David I ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Cancer Consortium   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atrasentan; Bevacizumab; Endothelin; Matrix metalloproteinases; Vascular endothelial growth factor

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; DOCETAXEL; ENDOTHELIN; EPHRIN; ESTRAMUSTINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PREDNISONE; PRINOMASTAT; REBIMASTAT; SORAFENIB; SUNITINIB; SURAMIN; TAXANE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ADRENAL DISEASE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; HEADACHE; HUMAN; KERATOPATHY; KIDNEY DISEASE; LIMB DEFECT; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; PERIPHERAL EDEMA; PROSTATE CARCINOMA; QUALITY OF LIFE; REVIEW; RHINITIS; SIDE EFFECT; TERATOGENESIS; THEORETICAL STUDY; THROMBOCYTOPENIA; TUMOR CELL; VALIDATION PROCESS; VEIN THROMBOSIS;

EID: 11144232324     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.027     Document Type: Review

References (147)

1. Jemal A, Tiwari R. C, Murray T, et al Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensidve metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22:2927-2941.
3. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46:142-148.
4. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
5. Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12:1868-1875.
6. Smaletz O, Scher H I, Small E, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20:3972-3982.
7. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-2513.
8. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001; 61:2177-2192.
9. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
11. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A 1994; 91:3497-3504.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
13. Risau W, Gautschi-Sova P, Bohlen P. Endothelial cell growth factors in embryonic and adult chick brain are related to human acidic fibroblast growth factor. EMBO J 1988; 7:959-962.
14. Yancopoulos GD, Klagsbrun M, Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998; 93:661-664.
15. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11:73-91.
16. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
17. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002; 3:411-423.
18. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60.
19. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286:2511-2514.
20. Stratmann A, Acker T, Burger A, et al. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer 2001; 91:273-282.
21. Gale NW, Baluk P, Pan L, et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 2001; 230:151-160.
22. Gerety SS, Wang HU, Chen ZF, et al. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999; 4:403-414.
23. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93:741-753.
24. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
25. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 1986; 46:467-473.
26. Day ED. Vascular relationships of tumor and host. Prog Exp Tumor Res 1964; 19:57-97.
27. Folkman J, Merler E, Abernathy C, et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275-288.
28. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
30. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, et al, eds. The Molecular Basis of Cancer. Philadelphia: WB Saunders, 1995:206-232.
31. van der Schaft DW, Seftor RE, Seftor EA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004; 96:1473-1477.
32. Hendrix MJ, Seftor EA, Hess AR, et al. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3:411-421.
33. Sharma N, Seftor RE, Seftor EA, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002; 50:189-201.
34. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node- negative breast carcinoma. J Clin Oncol 1994; 12:454-466.
35. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997; 157:2323-2328.
36. Silberman MA, Partin AW, Veltri RW et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79:772-779.
37. Mydlo JH, Kral JG, Volpe M, et al. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer preliminary results and therapeutic implications. Eur Urol 1998; 34:426-432.
38. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:401-409.
39. Borre M, Offersen BV, Nerstrom B, et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78:940-944.
40. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6:1882-1890.
41. Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999; 187:237-241.
42. Yu ED, Yu E, Meyer GE, et al. The relation of p53 protein nuclear accumulation and angiogenesis in human prostate cancer. Prostate Cancer Prostate Dis 1997; 1:39-44.
43. Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000; 45:216-224.
44. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93:208-213.
45. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51:161-167.
46. Mabjeesh NJ, Willard MT, Frederickson CE, et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9:2416-2425.
47. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
48. Joseph IB, Nelson JB, Denmeade SR, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3:2507-2511.
49. Stewart RJ, Panigrahy D, Flynn E, et al. Vascular endothelial growth factor expression and rumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165:688-693.
50. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998; 251:287-290.
51. Miao HQ, Lee P, Lin H, et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000; 14:2532-2539.
52. Richard C, Kim G, Koikawa Y, et al. Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells. Prostate 2002; 50:83-91.
53. Gagnon ML, Bielenberg DR, Gechtman Z, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A 2000; 97:2573-2578.
54. Ruiz M, Pettaway C, Song R, et al. Activator protein 2a inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 2004; 64:631-638.
55. Levine L, Lucci JA III, Pazdrak B, et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63:3495-3502.
56. Ferrer FA, Miller LJ, Lindquist R, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54:567-572.
57. Mazzucchelli R, Montironi R, Santinelli A, et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45:72-79.
58. Chevalier S, Defoy I, Lacoste J, et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 2002; 189:169-179.
59. Harper ME, Glynne-Jones E, Goddard L, et al. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996; 74:910-916.
60. Ismail AH, Altaweel W, Chevalier S, et al. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. Can J Urol 2004; 11:2146-2150.
61. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18:1440-1450.
62. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7:1932-1936.
63. Shariat SF, Anwuri VA, Lamb DJ, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004; 22:1655-1663.
64. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004; 22:499-506.
65. George DJ, Regan MM, Oh WK, et al. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004; 63:327-332.
66. Kohli M, Kaushal V, Spencer HJ, et al. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology 2003; 61:765-769.
67. Figg WD, Kruger EA, Price DK, et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002; 20:183-194.
68. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611.
69. Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 2001; 116:115-121.
70. Kearney JB, Kappas NC, Ellerstrom C, et al. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004; 103:4527-4535.
71. Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 2004; 96:875-878.
72. Shimizu K, Kubo H, Yamaguchi K, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 2004; 95:328-333.
73. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002; 62:854-859.
74. Sweeney P, Karashima T, Kim SJ, et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografrs via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8:2714-2724.
75. Huss WJ, Hanrahan CF, Barrios RJ, et al. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001; 61:2736-2743.
76. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004; 64:994-999.
77. Li R, Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004; 58:193-199.
78. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004; 10:5137-5144.
79. Holland SJ, Gale NW, Mbamalu G, et al. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 1996; 383:722-725.
80. Gale NW, Holland SJ, Valenzuela DM, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996; 17:9-19.
81. Davis S, Gale NW, Aldrich TH, et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994; 266:816-819.
82. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3:475-486.
83. Holmberg J, Frisen J. Ephrins are not only unattractive. Trends Neurosci 2002; 25:239-243.
84. Holmberg J, Clarke DL, Frisen J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 2000; 408:203-206.
85. Frisen J, Holmberg J, Barbacid M. Ephrins and their Eph receptors: multitalented directors of embryonic development. EMBO J 1999; 18:5159-5165.
86. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13:1055-1066.
87. Cowan CA, Henkemeyer M. Ephrins in reverse, park and drive. Trends Cell Biol 2002; 12:339-346.
88. Dravis C, Yokoyama N, Chumley MJ, et al. Bidirectional signaling mediated by ephrin-B2 and EphB2 controls urorectal development. Dev Biol 2004; 271:272-290.
89. Adams RH. Molecular control of arterial-venous blood vessel identity. J Anat 2003; 202:105-112.
90. Adams RH. Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 2002; 13:55-60.
91. Adams RH, Klein R. Eph receptors and ephrin ligands. essential mediators of vascular development. Trends Cardiovasc Med 2000; 10:183-188.
92. Adams RH, Diella F, Hennig S, et al. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 2001; 104:57-69.
93. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrin B ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13:295-306.
94. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996; 56:2185-2190.
95. Compagni A, Logan M, Klein R, et al. Control of skeletal patterning by ephrinB1-EphB interactions. Dev Cell 2003; 5:217-230.
96. Brambilla R, Schnapp A, Casagranda F, et al. Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases. EMBO J 1995; 14:3116-3126.
97. Fuller T, Korff T, Kilian A, et al. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 2003; 116:2461-2470.
98. Hamada K, Oike Y, Ito Y, et al. Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23:190-197.
99. Oates AC, Lackmann M, Power MA, et al. An early developmental role for eph-ephrin interaction during vertebrate gastrulation. Mech Dev 1999; 83:77-94.
100. O'Leary DD, Wilkinson DG. Eph receptors and ephrins in neural development. Curr Opin Neurobiol 1999; 9:65-73.
101. Berclaz G, Karamitopoulou E, Mazzucchelli L, et al. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 2003; 14:220-226.
102. Berclaz G, Andres AC, Albrecht D, et al. Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun 1996; 226:869-875.
103. Berclaz G, Altermatt HJ, Rohrbach V, et al. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 2001; 12:819-824.
104. Andres AC, Zuercher G, Djonov V, et al. A. Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Int J Cancer 1995; 63:288-296.
105. Nupponen NN, Kakkola L, Koivisto P, et al. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153:141-148.
106. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
107. Vlietstra RJ, van Alewijk DC, Hermans KG, et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58:2720-2723.
108. Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 2003; 97:874-879.
109. Lara PN Jr, Kung HJ, Gumerlock PH, et al. Molecular biology of prostate carcinogenesis. Crit Rev Oncol Hematol 1999; 32:197-208.
110. Daja MM, Niu X, Zhao Z, et al. Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis 2003; 6:15-26.
111. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43(suppl):S42-S51.
112. Nelson JB, Lee WH, Nguyen SH, et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997; 57:35-37.
113. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3:110-116.
114. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944-949.
115. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56:663-668.
116. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998; 4:50-57.
117. Pao MM, Tsutsumi M, Liang G, et al. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001; 10:903-910.
118. Jeronimo C, Henrique R, Campos PF, et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003; 56:52-55.
119. Mundy GR, Yin JJ, Mohammad KS, et al. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci U S A 2003; 100:10588-10589.
120. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003; 100:10954-10959.
121. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993; 53:2239-2248.
122. Takano S, Gately S, Neville ME, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54:2654-2660.
123. Kobayashi K, Vokes EE, Vogelzang NJ, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995; 13:2196-2207.
124. Voogd TE, Vansterkenburg EL, Wilting J, et al. Recent research on the biological activity of suramin. Pharmacol Rev 1993; 45:177-203.
125. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13:2174-2186.
126. Kelly WK, Scher HI, Mazumdar M, et al. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 1995; 13:2214-2222.
127. Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992; 10:881-889.
128. Clark JW, Chabner BA. Suramin and prostate cancer: where do we go from here? J Clin Oncol 1995; 13:2155-2157.
129. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol, 2001; 28:602-606.
130. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1888-1893.
131. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2532-2539.
132. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
133. Reese DM, Harris KA, Corry M, et al. A Phase II Trial of Humanized Anti-Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen-Independent Prostate Cancer. Prostate J 2001; 3:65-70.
134. Hu L, Hofmann J, Zaloudek C, et al. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161:1917-1924.
135. Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002; 8:3226-3231.
136. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22:393 (Abstract #1578).
137. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44:77-87.
138. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9:2587-2597.
139. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21:679-689.
140. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003; 9:2965-2972.
141. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. A. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003; 169:1143-1149.
142. Carducci MA, Nelson J, Saad F. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. Proc Am Soc Clin Oncol 2004; 23: (Abstract #4508).
143. Ahmann FR, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2001; 20:174a (Abstract #692).
144. Lara PN, Longmate J, Stadler W, et al. Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): a randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. Proc Am Soc Clin Oncol 2004; 23 (Abstract #4647).
145. Rosano L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003; 63:2447-2453.
146. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61:524-532.
147. Bagnato A, Cirilli A, Salani D, et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002; 62:6381-6384.